文献速递临床血液与体液分子诊断临床免疫

伴同种抗-D及RHD*DV.1等位基因患者的输血支持

Transfusion support for a patient with alloanti-D and the RHD*DV.1 allele.
PubMed 文献 · Clin Chim Acta · 2023-02-24

一例患有原发性胆汁性肝硬化、食管胃破裂出血的中国男性患者,血型血清学为O型D+,常规方法未检出抗体,输注D+红细胞无效。经MPT和LISS-IAT检出抗-D,RHD基因外显子测序确认其为DV Type 1型,提示减弱同种抗体导致输血无效。

要点

  • 常规IS和IAT未检出抗体时,输血无效需考虑减弱同种抗体可能。
  • MPT和LISS-IAT可提高抗-D检出敏感性。
  • RHD基因测序有助于确认DV型等位基因。

核心结论

  • 基因分型有助于支持自身抗体和同种抗体检测的特异性。
  • 结合更多血清学方法与分子技术进行血型鉴定有利于提高输血安全性和有效性。

研究设计与样本

  • 个案报告:一例中国男性患者,患有原发性胆汁性肝硬化、食管胃破裂和出血。

主要发现

  • 患者血清学血型为O型和D+,常规IS和IAT未检出自身抗体。
  • 输注D+红细胞无效,HGB短暂升高后四天内回落至50 g/L或更低。
  • 基因测序确认患者为DV Type 1型,RhD抗原凝集4+。
  • 血清和放散液中的抗-D仅能通过MPT(凝集2+)和LISS-IAT(凝集1+/3+)检出。

临床怎么用

  • 对常规方法未检出抗体但输血无效的患者,应结合MPT和LISS-IAT检测减弱同种抗体。
  • 必要时进行RHD基因测序以明确Rh血型变异型。

局限性

  • 为单个病例报告,结论需更多研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Safe blood transfusion is significantly affected by the complex antigen polymorphism and a high proportion of autoantibodies of the Rh blood group system. THE PATIENT AND METHODS: A male Chinese patient with primary biliary cirrhosis, esophageal and gastric rupture, and bleeding was admitted to our hospital. Blood typing identified that he had serological O and D+ blood groups. Because autoantibody was not detected using routine immediate spin (IS) and indirect antiglobulin test (IAT), he was treated by transfusing D+ red blood cells (RBCs). However, this treatment was ineffective. Thus, manual polybrene test (MPT) and low ionic salt solution indirect antiglobulin test (LISS-IAT) were performed, followed by exon sequencing of the RHD gene. RESULTS: The patient was confirmed as a DV Type 1 individual by gene sequencing, and had 4+ RhD antigen agglutination. The anti-D in serum and elution could only be detected by MPT (2+ agglutination) and LISS-IAT methods (1+/3+ agglutination). It was presumed that attenuated alloantibody contributed to ineffective RBC transfusion, causing a transient increase in hemoglobin (HGB) before falling back to 50 g/L or even lower within four days. CONCLUSION: Genotyping helps to support the specificity of detecting autoantibodies and alloantibodies. Combining more serological methods with molecular technology in blood typing is beneficial to improve the safety and effectiveness of blood transfusion.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Jiang L, Du Y, Hao K, et al. Transfusion support for a patient with alloanti-D and the RHD*DV.1 allele. Clin Chim Acta. 2023. PMID: 36841426. doi:10.1016/j.cca.2023.117268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。